|
|||||
|
|
A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors |
|
| Authors: | Bo Gao MD Mark Voskoboynik MD Adam Cooper MD Kate Wilkinson MD Siao Hoon MD Chih-Yi Hsieh MD Suixiong Cai PhD Ye Edward Tian PhD Jun Bao PhD Ning Ma MS Chen Wang MD Ming Zhang MS Baoyue Li PhD Mingchuan Guo MS Ruiyu Zhou MS Xiaozhu Wang MS Cong Xu PhD Paul de Souza PhD |
| Affiliation: | 1. Department of Medical Oncology, Blacktown Hospital and University of Sydney, Sydney, New South Wales, Australia;2. Medical Oncology, Nucleus Network, Melbourne, Victoria, Australia Central Clinical School, Monash University, Melbourne, Victoria, Australia;3. Western Sydney University Medical School, Campbelltown, New South Wales, Australia;4. IMPACT Therapeutics Inc., Shanghai, China |
| Abstract: | |
| Keywords: | Australia BRCA mutation PARP inhibitor recommended phase 2 dose senaparib solid tumors |